Clinical and Imaging Biomarkers Associated With Plasma ad Cellular Determinants of Cardiovascular Disease at the Time of COVID 19 (CARDIOCOVID)
Cardiovascular Diseases
About this trial
This is an interventional health services research trial for Cardiovascular Diseases focused on measuring Covid 19, Pneumonia
Eligibility Criteria
Inclusion Criteria: Women and men between the ages of 45 and 90; Patients diagnosed with cardiovascular disease; Patients with diabetes; Patients with dyslipidemia; Patients with hypertension, myocardial infarction (pre-existing or acute STEMI or NSTEMI event) chronic stable angina, peripheral vascular disease, stroke or TIA Exclusion Criteria: Inflammatory diseases and/or infections (except for the IMA-COVID-19 group); Tumors, immunological and/or hematological disorders; Ejection fraction less than 40%; Treatments with anti-inflammatory drugs, with the exception of low-dose aspirin, and antibiotic therapies up to 1 month before enrolment.
Sites / Locations
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Partecipants with cardiovascular disease
Partecip with cardiovascular disease and affected by COVID-19
The research program will examine imaging and clinical biomarkers associated with plasma and cellular determinants of cardiovascular disease, taking into account the potential effects of COVID-19 infection. This will make it possible to re-evaluate the cardiovascular risk profile of subjects with cardiovascular diseases.
In this arm we investigate the immune dysregulation that may play a role in the evolution of cardiovascular disease characteristics of chronic and convalescent COVID-19 participants, in this field we will perform detailed clinical cardiological and immunological phenotyping on enrolled patients.